Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis - 31/07/20
Doi : 10.1016/j.amjmed.2020.02.036
Paul J. Hauptman, MD a, ⁎ 
, Jonathan S. Wall, PhD a, Mathew S. Maurer, MD b
, Jonathan S. Wall, PhD a, Mathew S. Maurer, MD b a University of Tennessee Graduate School of Medicine, Knoxville Tenn
b Columbia University Irving Medical Center, New York NY
⁎Requests for reprints should be addressed to Paul J. Hauptman, MD, Dean, University of Tennessee Graduate School of Medicine, 1924 Alcoa Highway, U94, Knoxville, TN, 37920.University of Tennessee Graduate School of Medicine1924 Alcoa Highway, U94KnoxvilleTN37920
Le texte complet de cet article est disponible en PDF.
Plan
| Funding: None. |
|
| Conflicts of Interest: PJH reports consulting income from Abbott, Corvia, LivaNova, AstraZeneca, and Relypsa. JSW reports grant support from Ultragenyx Pharmaceutical, Caelum BioSciences, and Siemens; he is founder and unpaid chief scientific officer of Aurora Bio Inc and has patent rights in amyloid-reactive peptides and biologicals. MSM reports grant support from NIH HL HL139671-01, AG R21AG058348, and AG K24AG036778; gis institution received funding for clinical trials for Pfizer, Prothena, Eidos, and Alnylam; he has received consulting income from Pfizer, GSK, EIdos, Prothena, Akcea, and Alnylam. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 133 - N° 8
P. 892-894 - août 2020 Retour au numéro
Article précédent
- The Art of the Deal: Negotiating Consult Conflict
- Charlie M. Wray, Sanket S. Dhruva, Gurpreet Dhaliwal
- Artificial Intelligence: The Future for Diabetes Care
- Samer Ellahham
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?